Company intelligence / Profile preview
Naliean Therapeutics
Suzhou, Jiangsu, Chinanaliean.com ↗
- Ownership
- Private
- Employees
- ~7
- Development stage
- Other
01
Overview
Naliean Therapeutics is an oncology-focused biotech startup developing next-generation antibody-drug conjugates built on a nanobody-based multispecific platform. The company emphasizes modular ADC engineering, including multispecific targeting and dual-payload conjugation, to improve tumor penetration, selectivity, and therapeutic index versus conventional IgG-based ADCs. Its disclosed lead program, NL019, is a dual-target TROP2/Nectin-4 nanobody-based ADC for solid tumors. Public materials indicate that Naliean is focused on discovery and early-stage clinical development, with operations in China and a preclinical pipeline centered on cancer therapeutics.
- Therapeutic areas
- Oncology
- Modalities
- Antibody-drug conjugateBiologicNanobody therapy
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Naliean Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Naliean Therapeutics.